FLOVENT
LOE ApproachingNDAINHALATIONPOWDER
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
3/8 — Basic
FLOVENT by GSK is anti-inflammatory activity. First approved in 1997.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOVENT (fluticasone propionate) is an inhaled corticosteroid powder approved in 1997 for the treatment of asthma. It works via potent anti-inflammatory activity through glucocorticoid receptor binding, with 18-fold greater affinity than dexamethasone. The drug exhibits high local anti-inflammatory effect with negligible systemic bioavailability (<1%), making it suitable for chronic maintenance therapy.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30), signaling potential workforce consolidation within the brand team and shift toward generic transition planning.
Mechanism of Action
anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLOVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.